Advice for clinicians

Key findings

• Real-world refill timing data from a fully remote, HIW-accredited Welsh obesity clinic presented at the world's largest obesity medicine conference
• Analysis of prescription refill intervals and their relationship to treatment outcomes in patients receiving GLP-1 receptor agonist therapy
• Findings highlight the clinical importance of timely refills and proactive patient engagement in sustaining weight loss trajectories
• Data support the use of digital-first, high-touch remote models to optimise adherence in community-based obesity care

Key findings

• First real-world dataset from a UK remote obesity clinic examining de-escalation of GLP-1 receptor agonist therapy
• Characterises the clinical circumstances, patient profiles, and weight outcomes associated with dose reduction or treatment discontinuation
• Identifies predictors of successful de-escalation versus weight regain, informing evidence-based protocols for tapering
• Supports the development of structured de-escalation pathways within remote and community obesity services

Key findings

• Novel analysis of seasonal patterns in weight loss, weight regain, and treatment engagement from a real-world remote obesity clinic dataset
• Identifies clinically significant seasonal variation in patient outcomes, with implications for appointment scheduling and proactive clinical support
• Findings support the case for seasonally-aware obesity management protocols, particularly around high-risk periods such as Christmas and summer holidays
• Presented at Obesity Week 2026, the flagship annual conference of The Obesity Society and the American Society for Metabolic and Bariatric Surgery

Key findings

• 96% of patients remained on treatment for at least six months
• Average weight loss at six months was 19 kg
• Average dose of tirzepatide used was 7.7 mg, reflecting a gradual patient-centric titration approach

Key findings

• 91% of patients remained on therapy at 12 months
• Only 2% discontinued due to side effects — significantly lower than SURMOUNT-1 (6.2%) and STEP-1 (4.5%)
• Average weight loss was 24.8 kg, sustained across the cohort
• No A&E attendances or primary care consultations related to treatment were recorded
• No prescriptions required for the management of side effects

Key findings

• Structured education on mechanism of action was associated with reduced discontinuation
• Fewer side effects and no requirement for adjunctive prescribing
• Remote care, when grounded in education and real-time support, can match or exceed traditional models in safety, tolerability, and persistence

Key findings

• Large-scale real-world analysis of obesity prevalence and management patterns in UK primary care
• Part of the international IMPACT-O study, examining obesity treatment gaps across multiple countries
• Findings highlight the significant unmet need for effective obesity management in UK primary care settings
• Published in the International Journal of Obesity, co-authored with leading UK and international obesity researchers including Professor Kamlesh Khunti

Key findings

• Oral semaglutide demonstrated superior HbA1c reduction versus placebo in predominantly Chinese patients with type 2 diabetes
• Statistically significant body weight reductions observed with oral semaglutide
• Safety and tolerability profile consistent with the established GLP-1 receptor agonist class
• Findings support the use of oral semaglutide across diverse ethnic populations

Key findings

• Oral semaglutide resulted in greater time spent within the target glycaemic range compared with empagliflozin
• Exploratory analysis of the Phase 3 PIONEER 2 trial, presented at EASD 2021
• Findings support the clinical utility of oral semaglutide in achieving sustained glycaemic control in type 2 diabetes